If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> European Edition<br /> DERMATOLOGY<br /> Suppl. 2 February 2020 emjreviews.com<br /> + EADV 2019 & WCD 2019<br /> New Insights into<br /> Psoriasis Treatment<br /> Contents<br /> + EADV 2019<br /> Biologics in Moderate-to-Severe Psoriasis: Discover the Road to 3<br /> Long-term Control<br /> Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc 12<br /> Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly<br /> Population and Predictability From The reSURFACE 1 and reSURFACE 2<br /> Phase III Clinical Trials<br /> + WCD 2019<br /> Long-Term Safety of Tildrakizumab in Patients with Moderate-to-Severe 20<br /> Plaque Psoriasis through 3 Years (148 Weeks) from reSURFACE 1 and<br /> reSURFACE 2 Phase III Trials<br /> 2<br /> DERMATOL SUPPL • February 2020 • Cover Image © Yulia Grogoryeva / 123RF.com EMJ<br /> Biologic<a title="EMJ Dermatology. 2020 Suppl 2 page 1" href="http://viewer.zmags.com/publication/231ba1a9?page=1"> European Edition DERMATOLOGY Suppl. 2 Februar</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 2" href="http://viewer.zmags.com/publication/231ba1a9?page=2"> Contents + EADV 2019 Biologics in Moder</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 3" href="http://viewer.zmags.com/publication/231ba1a9?page=3"> Biologics in Moderate-to-Severe Psoriasis: Disco</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 4" href="http://viewer.zmags.com/publication/231ba1a9?page=4"> clinical studies. He emphasised the importance of</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 5" href="http://viewer.zmags.com/publication/231ba1a9?page=5"> Upstream target - Infrequent dosing - No rebound </a> <a title="EMJ Dermatology. 2020 Suppl 2 page 6" href="http://viewer.zmags.com/publication/231ba1a9?page=6"> treat psoriasis in a prospective nation</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 7" href="http://viewer.zmags.com/publication/231ba1a9?page=7"> IL-12/23 Cell membrane IFN-γ R IFN-α/βR </a> <a title="EMJ Dermatology. 2020 Suppl 2 page 8" href="http://viewer.zmags.com/publication/231ba1a9?page=8"> PsoBest showed that in a total of 2,444 patients </a> <a title="EMJ Dermatology. 2020 Suppl 2 page 9" href="http://viewer.zmags.com/publication/231ba1a9?page=9"> Question and Answer Session Q. Prof Thaçi queried</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 10" href="http://viewer.zmags.com/publication/231ba1a9?page=10"> the patient profile and patient’s preference into </a> <a title="EMJ Dermatology. 2020 Suppl 2 page 11" href="http://viewer.zmags.com/publication/231ba1a9?page=11"> 2014;23(10):705-9. 31. Teng MW et al. IL-12 and</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 12" href="http://viewer.zmags.com/publication/231ba1a9?page=12"> Tildrakizumab in Patients with Moderate-to-Severe</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 13" href="http://viewer.zmags.com/publication/231ba1a9?page=13"> Meeting Summary Tildrakizumab is a monoclonal ant</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 14" href="http://viewer.zmags.com/publication/231ba1a9?page=14"> 309 received 100 mg tildrakizumab, and </a> <a title="EMJ Dermatology. 2020 Suppl 2 page 15" href="http://viewer.zmags.com/publication/231ba1a9?page=15"> dose).9 Median time to loss of PASI 90 (≥90% impr</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 16" href="http://viewer.zmags.com/publication/231ba1a9?page=16"> Week 4 Week 8 Week 16 Week 28 Tildrakizumab</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 17" href="http://viewer.zmags.com/publication/231ba1a9?page=17"> Efficacy of Tildrakizumab According to Di</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 18" href="http://viewer.zmags.com/publication/231ba1a9?page=18"> myocardial infarction, non-fatal stroke, unstable</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 19" href="http://viewer.zmags.com/publication/231ba1a9?page=19"> https:/www.medicines.org.uk/emc/ product/9819/smp</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 20" href="http://viewer.zmags.com/publication/231ba1a9?page=20"> Long-Term Safety of Tildrakizumab in Patients</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 21" href="http://viewer.zmags.com/publication/231ba1a9?page=21"> part, parallel group, randomised, placebo-control</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 22" href="http://viewer.zmags.com/publication/231ba1a9?page=22"> Day -28 Day 1 Week 12 Week 28 Week 64/52 Week</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 23" href="http://viewer.zmags.com/publication/231ba1a9?page=23"> Table 1: Exposure-adjusted incidence rates (all p</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 24" href="http://viewer.zmags.com/publication/231ba1a9?page=24"> 0.24/2) for wound infection and 0.05 (CI: 0.00– 0</a> <a title="EMJ Dermatology. 2020 Suppl 2 page 25" href="http://viewer.zmags.com/publication/231ba1a9?page=25"> controlled trial. J Allergy Clin Immunol. 2015;13</a>